31 C
Vientiane
Sunday, May 11, 2025
spot_img
Home Blog Page 379

Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

SAN FRANCISCO and SUZHOU, China, March 31, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, as monotherapy for the treatment of unresectable locally advanced or metastatic mucosal or acral melanoma who have not received prior systemic therapy.

Recently, Innovent initiated and dosed the first patient for IBI363 in its first pivotal study to evaluate the efficacy and safety of IBI363 monotherapy versus pembrolizumab (Keytruda®) monotherapy in patients with unresectable, locally advanced or metastatic mucosal or acral melanoma who have not received prior systemic therapy. Furthermore, IBI363 has received two fast track designations (FTD) from the U.S. Food and Drug Administration (FDA), for the treatment of squamous non-small cell lung cancer and melanoma, respectively.

IBI363 has demonstrated outstanding efficacy signals in immunotherapy (IO)-naïve melanoma patients across two earlier clinical trials (Phase 1a/1b study NCT05460767 and Phase 2 study NCT06081920), which enrolled a total of 26 patients with advanced acral or mucosal melanoma:

  • The overall objective response rate (ORR) was 61.5%, and the disease control rate (DCR) was 84.6%—significantly higher than current domestic immunotherapy standards.
  • Prolonged follow-up revealed sustained tumor responses and long-term benefits, suggesting the potential superiority of IBI363 over existing standard therapies.

Dr. Hui Zhou, Senior Vice President of Innovent, said, “As Innovent’s first-in-class next-generation IO therapy, IBI363 simultaneously and selectively inhibits the PD-1/PD-L1 pathway and activates the IL-2 pathway. IBI363 has recently received multiple FTD and BTD designations, signifying regulatory recognition of its clinical value in addressing unmet medical needs. Non-cutaneous melanoma subtypes like mucosal melanoma—which are more prevalent in China—are particularly resistant to immunotherapy with limited clinical benefits[i]. We aim to validate IBI363’s potential in its first pivotal trial, through a head-to-head comparison with pembrolizumab, as a superior treatment option for melanoma patients over the current standard-of-care. We are also accelerating the global development of IBI363 across multiple tumor types, with the goal of extending the benefits of China’s innovation to patients worldwide.”

NMPA Breakthrough Therapy Designation is intended to facilitate and expedite the development and review of investigational drugs for serious diseases or conditions when preliminary clinical evidence indicates substantial improvement over current therapies. BTD qualifies a drug candidate for accelerated review by the CDE and provides the sponsor with timely advice and communication to expedite the approval process, helping to address the unmet clinical needs of patients more swiftly.

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)

IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 bispecific antibody fusion protein designed to enhance efficiency while minimizing toxicity. The IL-2 arm of IBI363 has been engineered to optimize therapeutic effects with reduced side effects, while the PD-1 binding arm enables PD-1 blockade and selective IL-2 delivery. By simultaneously inhibiting the PD-1/PD-L1 pathway and activating the IL-2 pathway, IBI363 facilitates more precise and efficient targeting and activation of tumor specific T cells. Preclinical studies have shown that IBI363 exhibits strong anti-tumor activity across multiple tumor-bearing pharmacological models, including those resistant to PD-1 inhibitors and metastatic models. Additionally, it has demonstrated a favorable safety profile in preclinical models.

Clinical trials of IBI363 are currently underway in China, the United States, and Australia to evaluate its safety, tolerability and preliminary efficacy in subjects with advanced malignancies. The first pivotal study of IBI363 has been initiated, for the treatment of IO-naive mucosal or acral melanoma.

Furthermore, IBI363 has received two fast track designations (FTD) from the U.S. FDA, for the treatment of melanoma and squamous NSCLC, respectively. IBI363 has also received breakthrough therapy designation from the NMPA of China for the treatment of melanoma.

About Melanoma

Melanoma is a malignant tumor that develops from melanocytes. Although melanoma accounts for only 3% of all types of skin cancer, it has the highest mortality rate of all types and is the most likely to metastasize. In China, the incidence and mortality rate of melanoma continue to rise. Melanoma is classified into three main subtypes: cutaneous, acral and mucosal. The characteristics of melanoma in Chinese patients differs greatly from those seen in European and American Caucasian populations in terms of pathogenesis, biological behavior, histological morphology, treatment response and prognosis[i]. For advanced cutaneous and acral melanomas, patients with the BRAF V600 mutation typically receive BRAF inhibitor combined with MEK inhibitors as the preferred molecular targeted therapy. For those without the BRAF V600 mutation, chemotherapy combined with anti-angiogenic drugs can be is a first-line treatment option. Notably, pembrolizumab has been approved as the first-line treatment indication for advanced melanoma in September 2024 in China, although clinical benefits are limited. For second-line treatment, therapies not previously used in first-line settings are recommended. Patients who have not received PD-1 monoclonal antibody in the first-line setting may be treated with PD-1 inhibitors as a second-line option. For advanced mucosal melanoma -which are more prevalent in China-are particularly resistant to immunotherapy with limited clinical benefits, in urgent need of new treatment options.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2Ramucirumab (Cyramza), Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References:

[i] CSCO黑色素瘤诊疗指南(2023年版)

TPIsoftware and GGI Technology Join Hands to Revolutionize Nam Cau Kien Industrial Park with ESG Solutions, Advancing Smart, Sustainable Industrial Development in Vietnam

TAIPEI, March 31, 2025 /PRNewswire/ — TPIsoftware (TWSE: 7781) and its Vietnam’s partner GGI technology have collaborated in a flagship project to implement AI-powered ESG solutions in Nam Cau Kien Industrial Park to reinforce the country’s commitment to sustainable development in the industrial sector. Following the signing between the key partners, the cross-national project aims to transform Vietnam’s first eco-industrial park, established in 2008, by deploying AI technologies to enhance environmental, social, and governance (ESG) practices, while supporting Vietnam’s goal to achieve net zero emissions by 2050.

Nguyen Thuy Anh (CEO, GGI Technology) and Pham Hong Diep (Chairman, Shinec) sealed the partnership agreement with a handshake after signing the contract, witnessed by Yvonne Chien (Executive Vice President of TPIsoftware), Do Vuong Phong (General Manager of TPIsoftware Vietnam), Dr. Nguyen Kim Anh (ESG expert), with the attendance of key leaders.
Nguyen Thuy Anh (CEO, GGI Technology) and Pham Hong Diep (Chairman, Shinec) sealed the partnership agreement with a handshake after signing the contract, witnessed by Yvonne Chien (Executive Vice President of TPIsoftware), Do Vuong Phong (General Manager of TPIsoftware Vietnam), Dr. Nguyen Kim Anh (ESG expert), with the attendance of key leaders.

Located in Hai Phong, Vietnam, Nam Cau Kien has attracted domestic and foreign investors due to its strategic location in the Northern coastal region and long-term sustainability initiatives. The park has partnered with GGI Technology, a leading environmental consultancy offering advice for GHG and ESG projects, to effectively implement ESG strategies. GreenSwift and ElectriSwift—sustainability solutions by TPIsoftware—have been incorporated into the park’s system for seamless greenhouse gas emissions management and improved energy efficiency.

As a key component of the sustainable development model, GreenSwift, an integrated carbon management platform, is utilized to automate carbon data collection, analysis, and reporting, ensuring carbon auditing efficiency and compliance with international frameworks such as ISO 14064 and the Intergovernmental Panel on Climate Change (IPCC). Complementing the initiative is ElectriSwift, an AI-powered energy management system, which provides real-time insights into energy consumption, identifies inefficiencies through anomaly detection based on acquired power usage patterns, improving overall ESG performance while reducing energy costs.

Ms. Nguyen Thuy Anh, CEO of GGI Technology, stated: “GGI’s mission is to accompany businesses on their journey toward sustainable green transformation, positioning ESG as a strategic foundation for growth. Nam Cau Kien is an ideal partner—bringing together vision, commitment, and determination to lead the green transition of Vietnam’s industrial sector.”

“Nam Cau Kien is committed to building the industrial park model of the future—where economic growth goes hand in hand with environmental and social responsibility,” affirmed Mr. Pham Hong Diep, Chairman of the Board of Directors at Shinec Joint Stock Company, the investor behind Nam Cau Kien Industrial Park. “We are joining hands to create a true ecological industrial park at Nam Cau Kien, spreading the spirit from Hai Phong to investors across the country, and inspiring a mindset of sustainable investment, investment for the future, where economic development is closely tied to environmental protection. This, in turn, helps build a symbiotic ecosystem that brings happiness to the community,” he emphasized.

Dr. Nguyen Kim Anh, ESG advisor and environmental remote sensing expert at the Vietnam Academy of Science and Technology, emphasized: “A truly green industrial park not only applies ESG principles but also requires a centralized management system that connects environmental, energy, and ecological security data on a single digital platform. The application of AIoT, artificial intelligence, remote sensing, and integrated one-stop technologies enables real-time monitoring, operational optimization, and ensures truly sustainable development.”

ElectriSwift’s implementation in Vietnam’s industrial park marks its global launch, with an upcoming plan to conduct a PoC (Proof of Concept) at the Tainan City Hall in southern Taiwan. This signifies ElectriSwift’s potential to be deployed across public and commercial infrastructure for enhanced utilization and optimization of renewable energy,” said Yilan Yeh, General Manager at TPIsoftware. “Our collaboration with Nam Cau Kien shows how we, as a B2B software leader, leverage our expertise in digital transformation solutions to help enterprises navigate the challenges of technological advancement, sustainable development and regulatory compliance. That is the spirit behind our ‘Tech for Change’ motto—harnessing the power of technology to drive sustainable transformation. It’s about creating smart, market-proven solutions that help organizations meet their ESG goals while building a more resilient and responsible future for the planet.”

 

Pudu Robotics Unveils FlashBot Arm: A Semi-Humanoid Embodied AI Service Robot for Commercial Applications

SHENZHEN, China, March 31, 2025 /PRNewswire/ — Pudu Robotics, a global leader in service robotics sector, has officially unveiled FlashBot Arm, an innovative Semi-Humanoid Embodied AI Service Robot tailored specifically for commercial service environments. Developed by Pudu X-Lab, the FlashBot Arm advances the capabilities of the company’s flagship FlashBot, combining advanced humanoid manipulation with intelligent delivery capabilities powered by cutting-edge embodied AI. This integration empowers the robot to autonomously perform a wide range of tasks in complex environments, including hotels, office buildings, restaurants, retail spaces, and healthcare facilities, marking a significant step forward for semi-humanoid robots in commercial applications.

FlashBot Arm: Semi-Humanoid Embodied AI Service Robot
FlashBot Arm: Semi-Humanoid Embodied AI Service Robot

Unlike traditional robots with limited mobility, the FlashBot Arm features real-time perception, decision-making, and execution capabilities, enabling it to create a closed-loop autonomous task system in dynamic settings. For example, in hotel environments where the lack of IoT systems or renovation constraints can hinder traditional robots’ ability to navigate elevators for cross-floor deliveries. FlashBot Arm revolutionizes this process through its robotic arms and dexterous end-effector capabilities, achieving fully autonomous workflows from item pickup to elevator operation and precision delivery, while its large language model-powered interaction system elevates service quality to unprecedented levels.

Key Features and Innovations:

  • Superior Manipulation Abilities: 

Equipped with two 7-degree-of-freedom robotic arms that can be lifted, FlashBot Arm achieves an operational reach of up to 2 meters. The robot boasts Pudu’s self-developed 11-degree-of-freedom dexterous hands, known as PUDU DH11, which afford it versatility and precision in finger manipulations, such as pressing buttons, grasping objects, and transporting items. This flexibility allows the robot to adapt effortlessly to various tasks without necessitating costly modifications to existing infrastructures.

  • Streamlined Delivery Operations: 

Featuring a wheeled chassis designed for exceptional mobility, FlashBot Arm enhances delivery efficiency significantly. By utilizing VSLAM and laser SLAM technologies, it generates accurate 3D maps, navigates autonomously, and avoids obstacles in real-time. Its closed delivery compartment ensures the safe transport of items, creating an end-to-end solution that optimizes workflow and boosts the productivity of human staff.

  • Embodied AI Decision-Making: 

Leveraging advanced large language models, FlashBot Arm engages in natural conversations with users, enabling human-like decision-making and task planning. When presented with a request, the robot can quickly analyze and decompose tasks while coordinating with other robots within the environment, ensuring efficient and collaborative execution.

  • Whole-Body Control for Superior Performance:

With Pudu’s extensive expertise in robotic systems integration, FlashBot Arm can simultaneously coordinate the movements of its chassis, robotic arms, and dexterous hand. This whole-body control enhances precision and task execution efficiency, allowing for real-time feedback and optimization that boosts the robot’s adaptability and responsiveness in complex environments.

  • Safety-First Design Features: 

FlashBot Arm is equipped with an array of high-precision sensors, including RGBD cameras, LiDAR, panoramic cameras, and pressure-sensitive skin, enabling dynamically perceive its surroundings. Coupled with advanced algorithms for dynamic motion planning, it achieves precise force control and stops immediately when encountering obstacles, thus ensuring safety in human-robot interactions.

  • Natural Multimodal Interaction:

Prioritizing user experience, FlashBot Arm offers multiple interaction modes, making it more approachable and user-friendly. Users can engage with the robot through AI-driven voice commands, gestures, and facial expressions, fostering natural communication. Its appealing design further enhances user engagement, reducing barriers for the public to easily access the benefits of embodied AI technology.

The introduction of the FlashBot Arm marks a major milestone for Pudu Robotics, accelerating the commercialization of humanoid embodied AI service robots. With its robotic arms and embodied intelligence capabilities, FlashBot Arm promises to enhance product functionalities and demonstrate remarkable versatility in various applications.

About Pudu Robotics

Pudu Robotics, a global leader in the service robotics sector, is dedicated to enhancing human productivity and living standards through innovative robot technology. With a focus on R&D, manufacturing, and sales of service robots, Pudu Robotics holds over a thousand authorized patents worldwide, encompassing a wide range of core technologies. The company’s robots have been widely adopted in various industries, including dining, retail, hospitality, healthcare, entertainment, education and manufacturing. To date, Pudu Robotics has successfully shipped over 90,000 units to a variety of markets, with a presence in more than 60 countries and regions worldwide. For more information on business developments and updates, follow PUDU on LinkedIn, Facebook, YouTube, Twitter and Instagram.

CAYIN Technology to Showcase E-Paper Integration and Cloud Digital Signage Solutions at 2025 Touch Taiwan

TAIPEI, March 31, 2025 /PRNewswire/ — CAYIN Technology is proud to announce its participation in 2025 Touch Taiwan, taking place from April 16 to 18 at Booth L702, 4th Floor, Nangang Exhibition Center Hall 1. The company will present its cutting-edge E-paper integration applications, professional digital signage solutions, and the GO CAYIN cloud-based content creation and playback system—ushering in a new era of intelligent visual communication.

2025 touch TAIWAN 鎧應科技
2025 touch TAIWAN 鎧應科技

Next-Gen Display Technology Driving Infinite Business Opportunities

With deep expertise in the field of digital signage, CAYIN is committed to delivering high-performance, stable, and flexible solutions. Visitors to the booth can expect to explore:

  • E-Paper Integration System – An energy-efficient, high-contrast display technology ideal for education, corporate, and healthcare environments.
  • Professional Digital Signage Solutions – Smart content management and automated scheduling across various industries including retail, hospitality, and enterprise.
  • GO CAYIN Cloud-Based Platform – A user-friendly interface that supports remote content editing, synchronized updates, and efficient information delivery.

An Invitation to Collaborate

Whether you’re exploring E-paper deployments, digital signage systems, or cloud-based visual management, we warmly invite you to visit us at Booth L702 to discover new collaboration opportunities.

Exhibition Details:

  • Date: April 16–18, 2025
  • Location: 4F, Nangang Exhibition Center Hall 1
  • Booth No.: L702

Book a meeting in advance and explore the future of smart display with us!

 

Human Frontier Science Program: Fellowships Awarded to 60 Pioneering Postdoctoral Scientists from 25 Nations

STRASBOURG, France, March 31, 2025 /PRNewswire/ — To foster the next generation of life science research, 60 of the world’s top emerging scientists from 25 nations have won 2025 Human Frontier Science Program (HFSP) Fellowships.

Human Frontier Science Program: Fellowships Awarded to 60 Pioneering Postdoctoral Scientists from 25 Nations
Human Frontier Science Program: Fellowships Awarded to 60 Pioneering Postdoctoral Scientists from 25 Nations

“We have awarded fellowships to some of the most creative early career scientists worldwide in order to open new frontiers in life science research,” said Guntram Bauer, HFSPO Chief Scientific Officer.

Postdoctoral scientists from these nations to receive 2025 HFSP Fellowships:

Australia

Mainland China

Hong Kong

Korea

Peru

Bangladesh

Egypt

India

Lithuania

Romania

Belgium

France

Israel

New Zealand

Spain

Brazil

Germany

Italy

Norway

United Kingdom

Canada

Ghana

Japan

Netherlands

United States of America

Online Booklet Lists Winners:

The 2025 HFSP Fellowship awards reflect the ingenuity and drive for discovery of the next generation of researchers. HFSP reviewed proposals from 541 applicants. To read the abstracts of the 60 awardees, click: 2025 HFSP Fellowships Awardees.

To find individual scientists, click: Index by Country of the Fellows.

Research highlights include:

  • Research on memory engrams, those groups of neurons that fire together and can distribute a memory across many neurons, will be the focus of a new study. Scientists will use brain machine interfaces to determine whether memories are preserved if some neurons are re-engineered.
  • An investigation on the symbiotic relationship of corals and dinoflagellates will show that critical nutrients are conveyed to the corals through protein glycosylation, for which microorganisms are provided safe harbor. This exchange is critical for coral reef health and may yield new insights for restoring and protecting coral reefs.
  • How bacteria mutate and acquire genetic material from hosts to resist antibiotics has been well studied; this new study evaluates how individual cells resist antibiotics. Scientists hope to better understand variability in cellular responses, which could also unlock insight regarding cancer and other diseases as well.

About HFSP Awards:

HFSP Long-Term Fellowships support scientists with a Ph.D. in a biological discipline to conduct a frontier project in the life sciences. Cross-Disciplinary Fellowships support scientists with a Ph.D. in a non-biological discipline (math, physics, computer science, etc.) to work on a frontier project in biology.

Journalists can view the full press release here.

CONTACT:
D. Rachael Bishop, HFSPO Science Writer and Editor 
rbishop@hfsp.org
+33 (0)7 81 87 62 21

ARTERY Technology Collaborates with Unitree Robotics to Advance Intelligent Robot Applications and Motor Control Systems

TAIPEI, March 31, 2025 /PRNewswire/ — With the rapid advancement of artificial intelligence and robotics technology, robots are accelerating their implementation in diverse application scenarios such as smart manufacturing, logistics and transportation, companion services, and public safety, becoming a key driver for future smart living and industrial upgrades. According to market research forecasts, the global robotics market is expected to exceed USD 100 billion by 2030, with bionic and multi-degree-of-freedom robots being the fastest-growing segments.

ARTERY's High-Performance MCUs Integrated into Unitree's Intelligent Robots
ARTERY’s High-Performance MCUs Integrated into Unitree’s Intelligent Robots

An intelligent robotic system can generally be divided into three major modules: control unit, sensing unit, and drive unit. These modules work closely together to construct a complete architecture capable of intelligent decision-making and precise control. Among them, the control unit serves as the core for decision-making and coordination and can be further divided into the “brain (MPU)” and “cerebellum (MCU)” layers: the MPU handles high-level tasks such as AI inference, visual recognition, and behavior planning, while the MCU focuses on real-time control and module communication, ensuring the coordination and stability of multi-axis movement.

The sensing unit is responsible for acquiring data from sensors such as IMU, pressure, and vision, and processes it through high-precision ADCs and analog signal front-end functions (such as OPA) for filtering and fusion, providing a decision-making basis for the control unit. The drive unit executes actual movements based on control instructions, managing servo motors and mechanical joints, and poses high-level control requirements to the MCU such as high-speed PWM output, position encoding input, and real-time feedback processing. Together, these three modules form the core loop of perception–decision–execution in intelligent robotics, forming the technological foundation for achieving high autonomy and agile mobility.

ARTERY Technology, aligning with this trend, has launched a variety of high-cost-performance 32-bit MCU products widely used in intelligent robot control and sensing modules, covering the following series:

ARTERY Intelligent Robotics MCU Solutions:

  • AT32F415 / AT32F403A / AT32F435 Series
    Built on the Arm® Cortex®-M4 processing core with clock speeds up to 288MHz, these MCUs integrate high-speed ADCs, rich PWM channels, and multiple communication interfaces such as CAN and UART. They are especially suited for high-degree-of-freedom joint control and multi-axis servo motor drive, enhancing motion coordination and real-time responsiveness.
  • AT32M412 Series
    Equipped with high-performance operational amplifiers (OPA), these MCUs can directly process analog signals from sensors such as acceleration, pressure, hearing, and vision, performing front-end filtering and amplification to improve sensing data fusion efficiency. This series is particularly suitable for applications integrating multiple sensing modules.

    The above MCU solutions have already been successfully deployed in intelligent robotics. Renowned bionic robot developer Unitree Robotics has adopted the AT32F415 as the joint control chip in the motor drive unit of its mass-production robots, significantly enhancing real-time control stability and overall system cost-effectiveness.

Looking ahead, ARTERY Technology will continue to deepen its involvement in the intelligent robotics market and actively develop an edge AI MCU platform integrated with neural processing units (NPU) to support local inference and edge learning capabilities.

About ARTERY Technology
Founded in 2016, ARTERY Technology is a high-performance microcontroller design company committed to driving global innovation in the market. With cutting-edge chip R&D capabilities, a comprehensive silicon IP portfolio, and extensive integration expertise, ARTERY has established R&D, sales, and technical support branches in Taiwan, Chongqing, Shenzhen, Suzhou, and Shanghai.

ARTERY’s microcontrollers are widely used in industrial control, motor drives, automotive electronics, consumer electronics, commercial applications, 5G, and the Internet of Things (IoT). Covering advanced power management, communication technologies, and AI intelligent control, ARTERY provides high-performance, highly reliable, and competitive solutions, shaping the future of smart technology.

AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance

HONG KONG, March 31, 2025 /PRNewswire/ — AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, 2025, the company recorded revenues of RMB 1,285 million in 2024, an increase of 8.2% compared to the previous year, with significant sales growth in its hepatitis B vaccine, hepatitis A vaccine, and quadrivalent meningococcal vaccine. The annual loss narrowed to RMB 278 million, demonstrating a substantial reduction of 85.7% in net losses, signaling a strong indication of an inflection point in performance.

Loss Narrowing by Nearly 90% with Core Products Maintaining Steady Growth

In the context of intensified competition in the domestic vaccine industry, AIM Vaccine’s Hansen yeast recombinant hepatitis B vaccine saw an increase in sales revenue, standing firm against market downturns. This achievement holds significant meaning for AIM Vaccine.

Since 2021, the company’s performance has faced continuous pressure due to intensified competition for core products and asset impairments. Therefore, some analysts believe that the substantial narrowing of losses in 2024 not only validates the effectiveness of AIM’s strategic adjustments but also provides a valuable window of time and funding for the commercialization of its subsequent R&D pipeline.

Optimistic assessments from professional institutions corroborate AIM’s actual development trends. According to a research report from Fosun International Securities, AIM’s core products, the hepatitis B vaccine and rabies vaccine, are expected to enter a stable growth phase in 2025. Meanwhile, the launch of new-generation innovative products, including the serum-free rabies vaccine, the 13-valent pneumococcal conjugate vaccine, the quadrivalent meningococcal conjugate vaccine, as well as mRNA-based respiratory syncytial virus (RSV) and shingles vaccines, is anticipated in the next 2-3 years, driving the company toward leapfrog development and value reassessment.

Three Iterative Major Vaccine Products Set to Launch, Driving Market Expansion

The narrowing of losses is just the starting point; AIM Vaccine’s true growth engine lies in the concentrated explosion of its iterative vaccine product matrix. Currently, three major innovative vaccine products are in the countdown for market launch.

The world’s first iterative serum-free rabies vaccine has completed Phase III clinical trials and has obtained the corresponding drug production license. The application for market registration has been formally submitted to the National Medical Products Administration. As it contains no animal serum, the vaccine significantly improves safety and reduces the likelihood of adverse reactions. According to the “Standard Operating Procedures for Rabies Exposure Prevention and Treatment (2023 Edition)” issued by the National Health Commission, rabies vaccination clinics are required to provide at least two different types of rabies vaccines. With its technological advantages in iteration, this product is expected to become the vaccine of choice for vaccination institutions.

The 13-valent pneumococcal conjugate vaccine (PCV13) has obtained the corresponding drug production license and has submitted a registration application to the National Medical Products Administration. Authoritative estimates suggest that the former “king of vaccines,” PCV13, has a global shortfall of up to 180 million doses, and due to the simultaneous commercialization layout in both domestic and international markets, this product will become an important growth point for AIM Vaccine.

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has completed the on-site work for Phase III clinical trials and plans to submit a pre-application for market registration to the National Medical Products Administration.

Aiming at the adult vaccine market, particularly in light of the “silver economy” wave, the iterative pneumococcal series products are expected to capture a market scale worth tens of billions.

Technological Innovation and International Strategy: A Dual Engine Driving Rapid Growth

Currently, AIM Vaccine’s technological reserves and market layout have demonstrated a bold development strategy to the market.

Fosun International Securities’ research report evaluates AIM’s R&D and production capabilities as follows: AIM Vaccine relies on five cutting-edge technology platforms (bacterial, viral, genetic engineering, conjugate, and mRNA vaccines) and GMP-certified high-standard large-capacity production facilities to ensure the stability of product quality and reliability of supply. Notably, the mRNA technology platform, successfully validated during the COVID-19 pandemic, has further solidified AIM’s leadership in the field of next-generation vaccine innovation, providing a solid foundation for future technological breakthroughs.

Using the globally focused mRNA technology platform as an example, according to the 2024 earnings announcement, AIM’s mRNA RSV vaccine and mRNA shingles vaccine have both been approved to conduct clinical trials in the United States, becoming powerful tools for accelerating the company’s internationalization.

Having already ventured into overseas markets, AIM Vaccine has started the registration process for its launched products in regions such as Southeast Asia, Africa, South America, and the Middle East. In 2024, the company successfully exported its rabies vaccine and quadrivalent meningococcal vaccine to countries like Egypt and Pakistan. With the launch of its iterative vaccines, AIM is expected to expand its international market through technological premiums, achieving a “Technology + Scale” dual.

 

FutureDial Partners with SB Frameworks to Drive Mobile Refurbishment Automation in Japan

SUNNYVALE, Calif., March 31, 2025 /PRNewswire/ — FutureDial, the global leader in connected device data sanitization, functional testing, and refurbishment automation, is proud to announce a strategic, multi-year partnership with SB Frameworks (SBF) Japan, a group company of SoftBank Corp., one of Japan’s most prestigious and innovative wireless operators. This collaboration will transform the second-hand mobile device market in Japan, setting a new benchmark for quality, efficiency, and automation in mobile refurbishment.

As Japan continues to lead the way in technological advancements, SBF is pioneering the future of mobile refurbishment by leveraging FutureDial’s industry-leading automation solutions. This partnership serves as a foundational step in SB Frameworks’ long-term vision to automate and scale mobile device renewal operations, ensuring premium quality, data security, and efficiency in the second-hand mobile market.

FutureDial: The Preferred Automation Partner for SB Frameworks

SB Frameworks, as an integral part of SoftBank’s extensive mobile ecosystem, has set forth an ambitious roadmap to modernize and scale mobile refurbishment operations. By partnering with FutureDial, the global leader in automation solutions for mobile device logistics, SBF is taking decisive steps toward an automated future, laying the foundation for long-term growth.

Why FutureDial?

 SB Frameworks selected FutureDial based on:

  • Industry Leadership & Proven Expertise – Over two decades of experience delivering best-in-class automation solutions for the mobile device supply chain.
  • Modular & Scalable Automation – A stepwise approach allowing SBF to progressively integrate automation for seamless adoption and long-term success.
  • Comprehensive Mobile Refurbishment Solutions – Covering everything from data erasure and diagnostics to functional testing and cosmetic inspection.
  • Commitment to Knowledge Transfer & Long-Term Success – FutureDial is dedicating significant resources to ensure SBF’s internal teams gain expertise, experience, and the capability to scale operations efficiently.

A Broad, Multi-Phase Partnership for the Future

This partnership is designed as a multi-year initiative, with multiple phases aimed at progressively automating and refining SBF’s mobile refurbishment processes. The initial focus will be on optimizing core operations, such as:

  • Automated Data Erasure & Security Compliance – Ensuring all personal data is fully removed from devices, adhering to Japan’s stringent privacy standards.
  • Advanced Functional Testing & Cosmetic Inspection – Implementing AI-driven diagnostics to enhance the grading and performance assessment of pre-owned devices.
  • Automated Receiving & Processing Solutions – Exploring next-generation automation for inbound device logistics, inventory management, and repair workflows.

“This partnership is a game-changer,” said Hiroyuki Arai, President and Representative Director at FutureDial. “SB Frameworks has a clear vision for automation, and FutureDial is honored to support them in executing a multi-year, multi-phase transformation that will set new industry standards in Japan.”

Hiro Watanuki, SB Frameworks’ President & CEO, echoed this sentiment: “Partnering with FutureDial aligns perfectly with our long-term strategy to enhance efficiency and drive automation across SB Frameworks’ mobile refurbishment ecosystem. We see this as a critical step in elevating our operations and reinforcing SBF’s leadership in the mobile sector.”

Looking Ahead: A Partnership Built for the Future

The FutureDial-SBF collaboration is just the beginning. As the partnership progresses, FutureDial will continue to introduce new automation solutions, integrate advanced AI-driven technologies, and optimize mobile device processing at scale.

More details on this initiative will be revealed in the coming months as FutureDial and SBF continue to lead the charge in automation and innovation.

For media inquiries, please contact:

Brad Treese

FutureDial PR Team

btreese@futuredial.com 

+1.415.623.8000

About FutureDial

FutureDial is the leading provider of automation solutions for mobile device processing, diagnostics, and refurbishment, helping businesses streamline operations, reduce costs, and enhance efficiency across the reverse logistics and circular economy. FutureDial’s AI-powered, modular automation solutions are used by mobile carriers, device resellers, and logistics companies worldwide.

About SB Frameworks

SB Frameworks (SBF) is a group company of SoftBank Corp., focused on mobile device refurbishment, logistics, and technology-driven solutions. As an innovator in Japan’s mobile industry, SBF is committed to advancing automation, sustainability, and operational excellence in the mobile device lifecycle.